γδ T cells: origin and fate, subsets, diseases and immunotherapy
Y Hu, Q Hu, Y Li, L Lu, Z Xiang, Z Yin… - … and Targeted Therapy, 2023 - nature.com
The intricacy of diseases, shaped by intrinsic processes like immune system exhaustion and
hyperactivation, highlights the potential of immune renormalization as a promising strategy …
hyperactivation, highlights the potential of immune renormalization as a promising strategy …
CTLs heterogeneity and plasticity: implications for cancer immunotherapy
Cytotoxic T lymphocytes (CTLs) play critical antitumor roles, encompassing diverse subsets
including CD4+, NK, and γδ T cells beyond conventional CD8+ CTLs. However, definitive …
including CD4+, NK, and γδ T cells beyond conventional CD8+ CTLs. However, definitive …
Gamma/delta T cells as cellular vehicles for anti-tumor immunity
CQ Wang, PY Lim, AHM Tan - Frontiers in Immunology, 2024 - frontiersin.org
Adoptive cellular immunotherapy as a new paradigm to treat cancers is exemplified by the
FDA approval of six chimeric antigen receptor-T cell therapies targeting hematological …
FDA approval of six chimeric antigen receptor-T cell therapies targeting hematological …
T cells in abdominal aortic aneurysm: immunomodulation and clinical application
W Gong, Y Tian, L Li - Frontiers in Immunology, 2023 - frontiersin.org
Abdominal aortic aneurysm (AAA) is characterized by inflammatory cell infiltration,
extracellular matrix (ECM) degradation, and vascular smooth muscle cell (SMC) dysfunction …
extracellular matrix (ECM) degradation, and vascular smooth muscle cell (SMC) dysfunction …
Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review
Regulatory T cells (Tregs) expressing the transcription factor FoxP3 are essential for
maintaining immunological balance and are a significant component of the …
maintaining immunological balance and are a significant component of the …
Novel potential therapeutic targets of alopecia areata
W Xu, S Wan, B Xie, X Song - Frontiers in Immunology, 2023 - frontiersin.org
Alopecia areata (AA) is a non-scarring hair loss disorder caused by autoimmunity. The
immune collapse of the hair follicle, where interferon-gamma (IFN-γ) and CD8+ T cells …
immune collapse of the hair follicle, where interferon-gamma (IFN-γ) and CD8+ T cells …
Decidual γδT cells of early human pregnancy produce angiogenic and immunomodulatory proteins while also possessing cytotoxic potential
J Nörenberg, P Vida, I Bösmeier, B Forró… - Frontiers in …, 2024 - frontiersin.org
During pregnancy, the maternal immune system must allow and support the growth of the
developing placenta while maintaining the integrity of the mother's body. The trophoblast's …
developing placenta while maintaining the integrity of the mother's body. The trophoblast's …
Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy
Y Wang, S Jin, Q Zhuang, N Liu, R Chen, SA Adam… - MedComm, 2023 - Wiley Online Library
Chimeric antigen receptor (CAR) T cells have been successfully used in adoptive cell
therapy for malignancies. However, some obstacles, including side effects such as graft …
therapy for malignancies. However, some obstacles, including side effects such as graft …
Targeting melanoma-associated fibroblasts (MAFs) with activated γδ (Vδ2) T cells: an in vitro cytotoxicity model
A Hajdara, U Çakır, B Érsek, P Silló, B Széky… - International Journal of …, 2023 - mdpi.com
The tumor microenvironment (TME) has gained considerable scientific attention by playing a
role in immunosuppression and tumorigenesis. Besides tumor cells, TME is composed of …
role in immunosuppression and tumorigenesis. Besides tumor cells, TME is composed of …
Human gamma-delta (γδ) T cell therapy for glioblastoma: A novel alternative to overcome challenges of adoptive immune cell therapy
Glioblastoma is the most common brain malignancy with devastating prognosis. Numerous
clinical trials using various target therapeutic agents have failed and recent clinical trials …
clinical trials using various target therapeutic agents have failed and recent clinical trials …